Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medicenna TherapeuticsMDNAF +10.34%29 Debt-to-Equity is 0.05 as of Mar. 2026, which is 400% above its 10-year median of 0.01. GuruFocus rates MDNAF with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 970 Biotechnology companies, Medicenna Therapeutics ranks better than 70.82% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Medicenna Therapeutics's Debt-to-Equity or its related term are showing as below:
MDNAF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.05
Current: 0.05
During the past 12 years, the highest Debt-to-Equity Ratio of Medicenna Therapeutics was 0.05. The lowest was 0.00. And the median was 0.01.
MDNAF's Debt-to-Equity is ranked better than 70.82% of 970
companies
in the Biotechnology industry
Industry Median: 0.15
vs MDNAF: 0.05
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Medicenna Therapeutics Debt-to-Equity Related Terms
Medicenna Therapeutics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Medicenna Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDNAF vs VRTX, REGN, RVMD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Medicenna Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicenna Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medicenna Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Medicenna Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medicenna Therapeutics (MDNAF) has a Debt-to-Equity of 0.05 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Medicenna Therapeutics and its competitors. This is 400% above median its historical median of 0.01. According to the industry distribution chart, Medicenna Therapeutics ranks #283 out of 970 companies in the Biotechnology industry, placing it in the top 29.2%.
Is Medicenna Therapeutics' Debt-to-Equity too high?
Medicenna Therapeutics' current Debt-to-Equity of 0.05 is 400% above median its 10-year median of 0.01. The Biotechnology industry median Debt-to-Equity is 0.15. Medicenna Therapeutics' value of 0.05 is 66.7% below this industry median. Based on the distribution chart, Medicenna Therapeutics ranks #283 out of 970 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Medicenna Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Medicenna Therapeutics' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medicenna Therapeutics ranks #283 out of 970 companies for Debt-to-Equity. This puts Medicenna Therapeutics in the upper half of its industry. The industry median Debt-to-Equity is 0.15. Medicenna Therapeutics' value of 0.05 is 66.7% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.15, Medicenna Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 970 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medicenna Therapeutics's current Debt-to-Equity of 0.05 is 66.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Medicenna Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicenna Therapeutics's current Debt-to-Equity is 0.05, which is 400% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicenna Therapeutics stock overvalued right now?
Medicenna Therapeutics (MDNAF) has a current Debt-to-Equity of 0.05. The current Debt-to-Equity is 0.05, which is 400% above median its 10-year median of 0.01 and 66.7% below the Biotechnology industry median of 0.15. Medicenna Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Medicenna Therapeutics (MDNAF), the current Debt-to-Equity is 0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL-13 Superkines and Empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. Its pipeline candidates include MDNA11 for Cancer immunotherapies, MDNA55 is a Molecular Trojan Horse, and BiSKITs represent a novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
29GF Score
Get the complete analysis for MDNAF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDNAF has been successfully added to your 
